Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,025,868 shares of the specialty pharmaceutical company’s stock after selling 139,700 shares during the period. Renaissance Technologies LLC’s holdings in Jazz Pharmaceuticals were worth $109,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its position in Jazz Pharmaceuticals by 48.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after purchasing an additional 398,549 shares during the period. Poehling Capital Management INC. raised its position in shares of Jazz Pharmaceuticals by 3.9% in the second quarter. Poehling Capital Management INC. now owns 21,691 shares of the specialty pharmaceutical company’s stock worth $2,315,000 after acquiring an additional 805 shares during the period. Thompson Siegel & Walmsley LLC raised its position in shares of Jazz Pharmaceuticals by 30.6% in the second quarter. Thompson Siegel & Walmsley LLC now owns 721,530 shares of the specialty pharmaceutical company’s stock worth $77,009,000 after acquiring an additional 168,957 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 64,096 shares of the specialty pharmaceutical company’s stock worth $6,841,000 after acquiring an additional 619 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 19.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 7,846 shares of the specialty pharmaceutical company’s stock worth $837,000 after acquiring an additional 1,272 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ JAZZ opened at $109.57 on Tuesday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.38. The stock has a market cap of $6.91 billion, a PE ratio of 22.59, a P/E/G ratio of 1.31 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The company has a 50-day moving average of $110.21 and a 200 day moving average of $111.20.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. As a group, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Piper Sandler decreased their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $173.07.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.